These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28985492)

  • 1. Primary cardiac diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression in an immunocompetent Chinese elderly woman.
    Wan Y; He D; Ye Y; Zhang W; Zhao S; Long Y; Chen M; Küçük C
    Cardiovasc Pathol; 2017; 31():54-56. PubMed ID: 28985492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological differences in MYC and BCL2 protein expression between primary extranodal and nodal diffuse large B-cell lymphoma.
    Sasaki Y; Murai S; Hayashi H; Kawamata N; Nagao K; Kuroiwa K; Narita H; Okamura R; Shimada S; Watanuki M; Arai N; Kawaguchi Y; Yanagisawa K; Shiozawa E; Yamochi T; Hattori N
    Pathol Res Pract; 2024 Aug; 260():155425. PubMed ID: 38964118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary cardiac diffuse large B-cell lymphoma in immunocompetent patients: clinical, histologic, immunophenotypic, and genotypic features of 3 cases.
    Soon G; Ow GW; Chan HL; Ng SB; Wang S
    Ann Diagn Pathol; 2016 Oct; 24():40-6. PubMed ID: 27649953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma.
    Kim YR; Yoon SO; Kim SJ; Cheong JW; Chung H; Lee JY; Jang JE; Kim Y; Yang WI; Min YH; Kim JS
    Ann Hematol; 2020 Sep; 99(9):2149-2157. PubMed ID: 32390113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 9. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
    Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
    Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
    PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas.
    Menguy S; Frison E; Prochazkova-Carlotti M; Dalle S; Dereure O; Boulinguez S; Dalac S; Machet L; Ram-Wolff C; Verneuil L; Gros A; Vergier B; Beylot-Barry M; Merlio JP; Pham-Ledard A
    Mod Pathol; 2018 Aug; 31(8):1332-1342. PubMed ID: 29581544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-MYC and BCL2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
    Akkaya B; Salim O; Akkaya H; Ozcan M; Yucel OK; Erdem R; Iltar U; Undar L
    Indian J Pathol Microbiol; 2016; 59(1):41-6. PubMed ID: 26960633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL.
    Shi QY; Feng X; Bao W; Ma J; Lv JH; Wang X; Rao Q; Shi QL
    J Neuropathol Exp Neurol; 2017 Nov; 76(11):942-948. PubMed ID: 29044419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.
    Naseem M; Asif M; Khadim MT; Ud-Din H; Jamal S; Shoaib I
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1103-1107. PubMed ID: 32334477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
    Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
    Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.
    Lu TX; Fan L; Wang L; Wu JZ; Miao KR; Liang JH; Gong QX; Wang Z; Young KH; Xu W; Zhang ZH; Li JY
    Oncotarget; 2015 Jul; 6(21):18374-88. PubMed ID: 26158410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.
    Testo N; Olson LC; Subramaniyam S; Hanson T; Magro CM
    Am J Dermatopathol; 2016 Oct; 38(10):769-74. PubMed ID: 27391453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
    Takahashi H; Miura K; Nakagawa M; Sugitani M; Amano Y; Kurita D; Sakagami M; Ohtake S; Uchino Y; Kodaira H; Iriyama N; Kobayashi S; Hojo A; Kobayashi Y; Hirabayashi Y; Kusuda M; Hatta Y; Nakayama T; Takei M
    Leuk Lymphoma; 2016 Dec; 57(12):2784-2790. PubMed ID: 27071312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma.
    Mohammed AA; Rashed HE; Abdelrahman AE; Obaya AA; Toam M; Abdel Nour HM; Abdelhamid MI; Elsayed FM
    Asian Pac J Cancer Prev; 2019 May; 20(5):1463-1470. PubMed ID: 31127909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.